Icatibant Fresenius (Icatibant Acetate)

Icatibant acetate is a selective antagonist of the bradykinin B2 receptor. By blocking this receptor on vascular endothelial cells, it prevents bradykinin‑mediated vasodilation and increased vascular permeability, thereby limiting the formation of edema that characterises hereditary angioedema attacks.

The dose is determined by the prescribing healthcare professional based on the patient’s clinical condition and local guidelines. Typically, a single subcutaneous injection is administered at the onset of an HAE attack, with additional doses considered only if the response is insufficient.

Safety data in pregnancy and lactation are limited. The product should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision should be made in consultation with a qualified healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, shipping details (including cold‑chain where applicable) and import documentation.

The primary alternative is C1‑inhibitor concentrate, which replaces the deficient protein. Icatibant works by blocking the downstream bradykinin receptor, offering a rapid, protein‑free option that can be self‑administered subcutaneously. Choice of therapy depends on patient preference, attack severity, and clinical guidelines.

Icatibant Fresenius must be stored refrigerated at 2‑8 °C. Keep the product in its original packaging, protect it from light, and do not freeze or shake the vial. If temporary temperature excursions occur, follow the manufacturer’s guidance before use.

The medication is given as a subcutaneous injection, usually into the abdomen or thigh. The injection site should be cleaned with an alcohol swab, and the needle inserted at a 45‑ to 90‑degree angle depending on the patient’s subcutaneous tissue thickness. Patients should be trained on proper technique by a healthcare professional.

Serious adverse events include anaphylaxis, severe hypotension, and laryngeal edema that can compromise the airway. Patients should be instructed to seek immediate medical attention if they experience difficulty breathing, swelling of the throat, sudden drop in blood pressure, or signs of a severe allergic reaction.

Icatibant Fresenius is contraindicated in individuals with a known hypersensitivity to icatibant acetate or any of the excipients in the formulation. It should also be avoided in patients for whom acute HAE treatment is not indicated, unless a prescriber determines a clear therapeutic benefit.